Bilateral Mastectomy — Surgical Removal of Both Breasts

Bilateral mastectomy entails the surgical excision of breast glandular tissue from both the left and right breasts. Depending on oncological necessity and anatomical factors, the operation may remove the skin, nipple-areolar complex, and underlying fascia, or preserve the skin envelope and nipple in skin-sparing or nipple-sparing techniques. Axillary lymph node staging, via sentinel lymph node biopsy, is frequently performed concurrently.

The operation is indicated either therapeutically—when disease affects both breasts concurrently or sequentially—or prophylactically. Risk-reducing bilateral mastectomy substantially lowers the incidence of breast cancer in high-risk individuals, though it cannot eliminate risk entirely because small amounts of microscopic breast tissue unavoidably remain along the chest wall.

Choosing a bilateral mastectomy involves balancing clinical risk reduction against significant physical changes, recovery time, and psychological adjustments. For therapeutic cases, it forms part of a curative plan. For preventive cases, it can reduce cancer risk by more than 90%, offering profound peace of mind. Discussing surgical options, reconstructive pathways, and sensory loss with breast and plastic surgeons empowers individuals to make informed decisions aligned with their personal priorities and lifestyle.

Decisions surrounding bilateral mastectomy are informed by mammograms, breast ultrasound, and contrast-enhanced breast MRI. Preoperative core biopsies confirm histological diagnosis, hormone receptor status (ER/PR), and HER2 expression. Comprehensive genetic testing, utilising germline multigene panels to identify inherited pathogenic variants, plays a vital role in identifying suitable candidates for contralateral prophylactic mastectomy.

This procedure relates predominantly to breast cancer, including invasive ductal carcinoma, invasive lobular carcinoma, and extensive ductal carcinoma in situ (DCIS). It is also heavily discussed among carriers of hereditary cancer syndromes linked to high breast cancer risk, such as those with BRCA1, BRCA2, PALB2, TP53 (Li-Fraumeni syndrome), or PTEN mutations.

Following surgery, tissue specimens are examined for clear margins and residual disease. Systemic therapies, such as adjuvant endocrine therapy, targeted agents, or chemotherapy, may still be recommended depending on cancer stage and biology. Conversely, preventive surgery often eliminates the need for ongoing intensive breast MRI screening, though chest wall clinical examinations remain part of long-term care.